Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

被引：131
作者：
Khan, RB
Shi, WJ
Thaler, HT
DeAngelis, LM
Abrey, LE
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
JOURNAL OF NEURO-ONCOLOGY | 2002年 / 58卷 / 02期
关键词：
primary CNS lymphoma; intrathecal chemotherapy; methotrexate; neurotoxicity;
D O I：
10.1023/A:1016077907952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.
引用
收藏
页码：175 / 178
页数：4
相关论文
共 11 条
  • [1] Treatment for primary CNS lymphoma: The next step
    Abrey, LE
    Yahalom, J
    DeAngelis, LM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3144 - 3150
  • [2] LEPTOMENINGEAL TUMOR IN PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - RECOGNITION, SIGNIFICANCE, AND IMPLICATIONS
    BALMACEDA, C
    GAYNOR, JJ
    SUN, M
    GLUCK, JT
    DEANGELIS, LM
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (02) : 202 - 209
  • [3] Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases
    Chamberlain, MC
    Kormanik, PA
    Barba, D
    [J]. JOURNAL OF NEUROSURGERY, 1997, 87 (05) : 694 - 699
  • [4] METHOTREXATE CEREBROSPINAL-FLUID AND SERUM CONCENTRATIONS AFTER INTERMEDIATE-DOSE METHOTREXATE INFUSION
    EVANS, WE
    HUTSON, PR
    STEWART, CF
    CAIRNES, DA
    BOWMAN, WP
    RIVERA, G
    CROM, WR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) : 301 - 307
  • [5] RANDOMIZED PROSPECTIVE COMPARISON OF INTRAVENTRICULAR METHOTREXATE AND THIOTEPA IN PATIENTS WITH PREVIOUSLY UNTREATED NEOPLASTIC MENINGITIS
    GROSSMAN, SA
    FINKELSTEIN, DM
    RUCKDESCHEL, JC
    TRUMP, DL
    MOYNIHAN, T
    ETTINGER, DS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 561 - 569
  • [6] Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients
    Guha-Thakurta, N
    Damek, D
    Pollack, C
    Hochberg, FH
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1999, 43 (03) : 259 - 268
  • [7] Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
    Hiraga, S
    Arita, N
    Ohnishi, T
    Kohmura, E
    Yamamoto, K
    Oku, Y
    Taki, T
    Sato, M
    Aozasa, K
    Yoshimine, T
    [J]. JOURNAL OF NEUROSURGERY, 1999, 91 (02) : 221 - 230
  • [8] Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study
    Mahoney, DH
    Shuster, JJ
    Nitschke, R
    Lauer, SJ
    Steuber, CP
    Winick, N
    Camitta, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) : 1712 - 1722
  • [9] Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma
    McAllister, LD
    Doolittle, ND
    Guastadisegni, PE
    Kraemer, DF
    Lacy, CA
    Crossen, JR
    Neuwelt, EA
    [J]. NEUROSURGERY, 2000, 46 (01) : 51 - 60
  • [10] CENTRAL NERVOUS-SYSTEM METASTASES FROM NON-HODGKINS LYMPHOMA - TREATMENT AND PROPHYLAXIS
    RECHT, L
    STRAUS, DJ
    CIRRINCIONE, C
    THALER, HT
    POSNER, JB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1988, 84 (03) : 425 - 435
12